Fractalkine Receptor Antagonist KAND567
Peritoneum Cancer
Novakand Pharma ABSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 81/ 100
Competitive context
34 Active assets in the Peritoneum Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Peking University | Phase 2 | BB |
Docetaxel University of Pittsburgh | Phase 2 | BB |
FLUOROURACILUM City of Hope Medical Center | Phase 3 | BB |
Mirvetuximab Soravtansine AbbVie | Phase 3 | BB |
Carboplatin Qilu Hospital of Shandong University | Phase 3 | BB |
View all 49 →
Same molecule, other indications
Fractalkine Receptor Antagonist KAND567 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →